Theravance Biopharma, Inc. Retained Earnings
Theravance Biopharma, Inc. (TBPH) had Retained Earnings of -$870.46 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$870.46M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$864.56M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$859.63M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$920.65M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$870.46M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$864.56M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$859.63M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$920.65M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$924.27M 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$979.10M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$965.52M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$950.00M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$937.30M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$920.77M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$909.10M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$900.59M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$891.64M 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$876.00M 10-Q · filed 2023-05-10 |
| 2022-12-31 | -$853.91M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$843.55M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$1.76B 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$1.75B 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$1.73B 10-K · filed 2023-03-01 |
| 2021-09-30 | -$1.69B 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$1.66B 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$1.61B 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$1.53B 10-K · filed 2022-02-28 |
| 2020-09-30 | -$1.47B 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$1.39B 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$1.33B 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$1.25B 10-K · filed 2021-02-26 |
| 2019-09-30 | -$1.18B 10-Q · filed 2019-11-08 |
| 2019-06-30 | -$1.12B 10-Q · filed 2019-08-05 |
| 2019-03-31 | -$1.08B 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$1.01B 10-K · filed 2020-02-27 |
| 2018-09-30 | -$961.96M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$902.53M 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$861.71M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$797.74M 10-K · filed 2019-02-28 |
| 2017-09-30 | -$710.82M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$643.94M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$577.65M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$512.23M 10-K · filed 2018-02-28 |
| 2016-09-30 | -$444.89M 10-Q · filed 2016-11-09 |
| 2016-06-30 | -$410.93M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$363.71M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$321.56M 10-K · filed 2017-03-01 |
| 2015-09-30 | -$276.73M 10-Q · filed 2015-11-12 |
| 2015-06-30 | -$229.41M 10-Q · filed 2015-08-13 |
| 2015-03-31 | -$181.81M 10-Q · filed 2015-05-13 |
| 2014-12-31 | -$139.34M 10-K · filed 2016-03-11 |
| 2014-09-30 | -$75.03M 10-Q · filed 2014-11-12 |
| 2014-06-30 | -$20.53M 10-Q · filed 2014-08-14 |
| 2013-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |